Phase 1/2 × INDUSTRY × Gastrointestinal × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 6 FDA
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA
NCT05267626 2026-03-31

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled